CRISPR Therapeutics to Present at Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following presentations in September:
Citi’s 13th Annual Biotech Conference
Panel: Genome Editing
Date: Wednesday, September 5, 2018
Presentation: 1:15 PM ET
Location: Boston, Massachusetts
Jefferies Gene Therapy Summit
Date: Thursday, September 27, 2018
Location: New York, NY
A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of each webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACTS Media Contact: Jennifer Paganelli WCG on behalf of CRISPR 347-658-8290 firstname.lastname@example.org Investor Contacts: Susan Kim 617-307-7503 email@example.com
Source: CRISPR Therapeutics AG
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.